However, despite these encouraging findings, there remains a gap in understanding whether CXCR4 antagonists can effectively address peripheral blood neutropenia, abnormal BM neutrophil counts, and infection susceptibility specifically in patients harboring CXCR2 LOF variants. The gene discussed is CXCR2; the disease is Decreased total neutrophil count.